Please login to the form below

Not currently logged in

Roche appoints Pamela Carroll as global head of pathways biology

She will also act as oncology discovery site head at Roche's Nutley, New Jersey research facility

Pamela Carroll has joined Swiss pharmaceutical company Roche as global head of pathways biology within its Pharma Research and Early Development unit.

Carroll will also act as oncology discovery site head at Roche's Nutley, New Jersey research facility.

She first joined the pharma industry in 1999, taking up a position in applied genomics at Bristol-Myers Squibb, and subsequently moved to Merck Research Laboratories as director and department head of cancer pathways.

In 2009 Carroll moved to the Belfer Institute of Applied Cancer Sciences at Dana Farber Cancer Institute, Harvard Medical School, where she was head of research and a member of the senior leadership team.

Mike Burgess, global head oncology, Discovery and Translational Area, and head, large molecule research at Roche, said: "With more than a decade's industry experience concentrated in cancer, Pam has built a reputation for scientific excellence and leadership in the field.

"Her broad knowledge and successful history in leading oncology drug discovery efforts make her is an ideal fit for this position."
As pathways biology head, Carroll will have global responsibility for pathway validation efforts and ensuring Roche's oncology discovery and translational area develops robust preclinical models to evaluate pathways.

Meanwhile, as oncology discovery site head at the Nutley site she will also be responsible for designing and implementing research studies focused on new or improved oncology medicines, including small molecules and biologics.

She will also direct drug discovery research, help develop oncology objectives for Nutley and contribute to the development of the Roche's global discovery oncology strategy.

8th November 2011


Featured jobs

Subscribe to our email news alerts


Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...